CSL Limited has reported positive top-line results from a pediatric study of ANDEMBRY, or garadacimab-gxii, in children aged 2 to 11 years with hereditary angioedema. The Australian-listed biotechnology company said the findings support planned regulatory submissions seeking to expand the treatment’s current label beyond patients aged 12 years and older.
The announcement advances ANDEMBRY from an established adult and adolescent therapy toward a potentially broader pediatric franchise, but the disclosed evidence remains preliminary. CSL has not yet released numerical attack rates, detailed adverse-event findings, pharmacokinetic results, confidence intervals or participant-level outcomes, meaning the commercial and regulatory significance cannot be fully assessed from the top-line statement alone.
The company plans to begin submitting pediatric filings during the first half of its financial year, which runs through December 2026, and intends to present the complete study findings at a future scientific congress before seeking peer-reviewed publication. Application submission would represent an important regulatory step, although it would not itself establish that authorities will approve the proposed age-specific doses or grant an identical pediatric indication across markets.
What do CSL’s positive pediatric ANDEMBRY results actually establish at this stage?
The multicentre, open-label study enrolled 22 children with hereditary angioedema and followed them during a 12-month treatment period. Sixteen participants aged 6 to 11 received 100 mg of ANDEMBRY once monthly, while six children aged 2 to 5 received 100 mg every two months. CSL reported that the treatment’s safety and tolerability profile was consistent with earlier studies and that most participants remained free from hereditary angioedema attacks during treatment.
Those results are encouraging, particularly because the study covered a full year and included children as young as two. However, “the majority” is not sufficiently precise to determine the magnitude or consistency of the response. The top-line disclosure does not state how many children remained completely attack-free, how baseline attack frequency was established, whether outcomes differed between the two age cohorts or how many participants required rescue medication.
The ClinicalTrials.gov record identifies safety, pharmacokinetics, pharmacodynamics and efficacy as central study objectives. Its primary outcome measures include the number and percentage of participants experiencing treatment-emergent adverse events, while secondary measures examine reductions in time-normalised hereditary angioedema attack rates, including thresholds of at least 50%, 70%, 90% and complete attack freedom.
That design means the regulatory value of the study is likely to depend on more than the attack-free proportion. Authorities will examine whether the selected pediatric regimens produced drug exposure and biological activity comparable with levels associated with efficacy in older patients, while also reviewing adverse events, laboratory findings, hypersensitivity, immunogenicity and treatment discontinuations.
CSL has described the results as coming from a Phase 3b study, while the public trial registry categorises protocol CSL312_3003 as a Phase 3, open-label, single-group study. The difference in nomenclature does not alter the basic evidence hierarchy: this was not a randomised, blinded or placebo-controlled pediatric efficacy trial.
Why will the age-specific ANDEMBRY dosing schedules receive close regulatory scrutiny?
ANDEMBRY works by inhibiting activated factor XII, or factor XIIa, near the beginning of the biological cascade that produces bradykinin-mediated swelling in hereditary angioedema. This upstream mechanism differentiates garadacimab from treatments that inhibit plasma kallikrein, replace C1 esterase inhibitor or target other parts of the pathway.
The pediatric study used a lower amount and less frequent administration than the currently authorised regimen for older patients. Children aged 6 to 11 received 100 mg monthly, while the youngest group received the same amount once every two months. This suggests the development programme was designed to match exposure and pharmacodynamic activity across age groups rather than simply applying the adult dose to smaller patients.
The complete pharmacokinetic dataset will therefore be central to the filing. Regulators are likely to examine peak and trough concentrations, factor XIIa inhibition, exposure variability and whether the two-month interval maintained adequate activity in the youngest cohort throughout the dosing period. Results based only on average exposure could be less persuasive if a small number of children experienced substantially lower concentrations or breakthrough attacks before their next dose.
The age cohorts were also unevenly sized. Only six participants were aged 2 to 5, which limits the amount of direct safety information available for the group receiving the least frequent regimen. Small samples are common and sometimes unavoidable in rare pediatric diseases, but they place greater importance on biological bridging, prior experience in older patients and carefully designed post-authorisation monitoring.
Practical administration will also matter. In the United States, the currently licensed ANDEMBRY presentations contain 200 mg in a single-use prefilled syringe or autoinjector. CSL has not explained in its top-line announcement how a commercial 100 mg pediatric dose would be supplied, whether a separate presentation is planned or how caregiver administration would be managed.
That is not necessarily a regulatory obstacle, but it is an execution question that must be resolved before launch. A pediatric label involving a new strength, delivery device or instructions for use may require additional human-factors, stability, manufacturing and packaging information alongside the clinical package.
How could ANDEMBRY compete in the pediatric hereditary angioedema market?
ANDEMBRY is currently approved in the United States for prophylaxis against hereditary angioedema attacks in adults and pediatric patients aged 12 years and older. The United States Food and Drug Administration approved garadacimab-gxii in June 2025, while the European Union authorisation covers routine prevention of recurrent attacks in adults and adolescents from age 12.
A successful label expansion would increase ANDEMBRY’s eligible population and allow CSL Behring to present a more continuous treatment pathway across childhood, adolescence and adulthood. It could also strengthen the company’s broader hereditary angioedema portfolio, which already includes the C1 esterase inhibitor product HAEGARDA.
However, ANDEMBRY would not be the first preventive therapy available to very young hereditary angioedema patients. In the United States, Takeda Pharmaceutical Company’s TAKHZYRO, or lanadelumab-flyo, has been approved for patients aged two and older since 2023. BioCryst Pharmaceuticals’ oral therapy ORLADEYO, or berotralstat, received an expanded United States indication in December 2025 covering patients aged two and older.
Other established options include HAEGARDA and CINRYZE, both of which have pediatric indications beginning at age six in the United States. The market is therefore becoming segmented not simply by age, but also by administration route, dosing frequency, mechanism, patient preference, caregiver workload, attack control, reimbursement and physicians’ familiarity with each product.
ANDEMBRY’s potential differentiator in the youngest children would be the proposed once-every-two-months regimen. If the full evidence confirms sustained control across that interval, the dosing schedule could reduce the number of preventive injections required annually. Yet a convenience advantage cannot be assumed solely from frequency because product preparation, injection experience, breakthrough-attack management and family preferences also influence treatment selection.
The commercial opportunity may therefore be meaningful but incremental rather than uncontested. CSL must demonstrate that the factor XIIa mechanism, dosing schedule and complete safety package provide enough differentiation to win physician confidence and payer access in a market where effective pediatric alternatives already exist.
Which evidence gaps must be addressed before regulators assess an expanded label?
The most immediate limitation is the absence of detailed safety data. CSL said the pediatric profile was favourable and consistent with prior studies, but it did not disclose treatment-emergent adverse-event rates, serious adverse events, injection-site reactions, hypersensitivity events, withdrawals or antidrug antibodies. The statement also did not identify whether any events differed by age group.
The current United States safety information identifies injection-site reactions, abdominal pain and nasopharyngitis among the most common adverse effects in the authorised population. Those findings cannot automatically be assumed to occur at the same frequency or severity in younger children, particularly when a different dose and dosing interval are being used.
The single-arm design is another limitation. Without a concurrent placebo or active-control group, attack reductions must be interpreted against participants’ documented pretreatment histories. Hereditary angioedema attack frequency can vary over time, making baseline definition, observation duration and attack adjudication important to understanding the reported response.
A majority attack-free result could be clinically persuasive if it is supported by consistent reductions across all participants, low rescue-treatment use and durable pharmacodynamic coverage. It would be less informative if a small number of children accounted for most residual attacks or if treatment response weakened near the end of the dosing interval. The congress presentation will need to show the distribution of outcomes, not merely the cohort average.
The small enrolment also makes detection of uncommon safety events difficult. Regulators may consequently rely on the larger safety database in adolescents and adults, supported by pediatric pharmacokinetic bridging and post-market commitments. That approach is common in rare-disease development, but the acceptability of extrapolation depends on whether disease biology, treatment response and exposure relationships are sufficiently comparable across ages.
Why is this pediatric readout strategically useful for CSL despite its limited size?
ANDEMBRY is important to CSL because it is the first monoclonal antibody discovered and developed internally by the company from early research through commercial product. CSL has positioned it as a growth asset within its rare-disease business and as evidence that its research organisation can produce proprietary medicines beyond its traditional plasma-derived portfolio.
Expanding the label could extend the product’s commercial lifecycle, support greater specialist familiarity and make ANDEMBRY relevant earlier in the treatment journey. Pediatric use can also reinforce relationships with hereditary angioedema centres, clinicians and patient organisations, creating continuity as children move into adolescent and adult care.
The opportunity should nevertheless be kept in proportion. Hereditary angioedema is rare, and the addressable pediatric group is smaller still. Approval would broaden the franchise, but meaningful revenue will depend on diagnosis rates, geographic reimbursement, competitive contracting and the pace at which clinicians switch younger patients from established options.
For investors, the data represent regulatory de-risking rather than a stand-alone transformation of CSL’s earnings outlook. CSL shares closed at A$119.52 on July 28, 2026, rising 2.69% during the session after the announcement. Based on available closing prices, the stock remained about 1.5% lower over five trading sessions but approximately 3.6% higher over one month, with a reported 52-week range of A$90.00 to A$275.79.
The daily rebound shows that the market welcomed the update, but the share price remains much closer to its 52-week low than its high. Investor sentiment is therefore unlikely to be reset by a 22-patient pediatric study alone. Attention will also remain on CSL’s broader operating performance when the company releases its full-year results on August 18, 2026.
What milestones will determine whether ANDEMBRY’s pediatric programme becomes commercially meaningful?
The first milestone will be the start of regulatory submissions during the half-year ending December 2026. CSL will need to define the jurisdictions included in the initial filing wave, the exact proposed indication, the dosing instructions for each pediatric age group and the commercial presentation intended to deliver the 100 mg dose.
The second milestone will be disclosure of the full study dataset. Investors and clinical observers will look for the precise number of attack-free participants, baseline and on-treatment attack rates, responder thresholds, rescue-medication use, age-cohort consistency, adverse events, immunogenicity and exposure-response findings.
Regulatory decisions will then determine whether authorities accept the proposed two-month dosing interval for children aged 2 to 5 and whether the label is granted across the full 2 to 11 age range. Different regulators could reach different conclusions or request different formulations, monitoring arrangements or post-authorisation evidence.
CSL’s top-line result has moved ANDEMBRY closer to a broader pediatric role, but it has not completed the evidence story. The decisive question is no longer whether the company saw an encouraging signal in 22 children. It is whether the complete safety, pharmacokinetic and attack-control package is strong enough to support the proposed doses, satisfy regulators and differentiate ANDEMBRY in an increasingly competitive pediatric hereditary angioedema market.
